^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    famitinib (SHR 1020)

    i
    Other names: SHR 1020, SHR-1020, SHR1020
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    Apply
    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N) (NCT05582499)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    11/01/2022
    Primary completion :
    12/31/2024
    Completion :
    09/01/2025
    HER-2 • PGR • CD8 • FOXC1
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab (NCT06516289)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    12/12/2024
    Initiation :
    09/30/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    BRCA
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466
    A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (NCT05999149)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    08/20/2023
    Primary completion :
    08/30/2025
    Completion :
    08/30/2027
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)
    SNF Platform Study of HR+/ HER2-advanced Breast Cancer (BCTOP-L-M05) (NCT05594095)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    12/30/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HER-2 • ER • PGR
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive
    |
    sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)
    Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (BCTOP-T-M02) (NCT05760378)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    03/17/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • AiRuiKa (camrelizumab) • capecitabine • eribulin mesylate • famitinib (SHR 1020)
    An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER) (NCT04395989)
    Phase 2
    Fudan University
    Active, not recruiting
    Last update posted :
    12/22/2023
    Initiation :
    07/28/2020
    Primary completion :
    05/31/2023
    Completion :
    12/31/2024
    HER-2
    |
    HER-2 expression • PGR expression
    |
    Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)
    Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor (NCT04346381)
    Phase 2
    Jiangsu HengRui Medicine Co., Ltd.
    Completed
    Last update posted :
    09/18/2023
    Initiation :
    06/05/2020
    Primary completion :
    06/22/2022
    Completion :
    06/22/2022
    PD-L1
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer (NCT05176080)
    Phase 1/2
    Henan Cancer Hospital
    Active, not recruiting
    Last update posted :
    05/04/2023
    Initiation :
    12/08/2021
    Primary completion :
    05/30/2024
    Completion :
    01/30/2026
    HER-2
    |
    HR positive • HER-2 negative
    |
    fulvestrant • AiRuiKang (dalpiciclib) • famitinib (SHR 1020)
    A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. (NCT04733417)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Active, not recruiting
    Last update posted :
    04/12/2023
    Initiation :
    05/26/2021
    Primary completion :
    08/30/2022
    Completion :
    09/30/2023
    HER-2
    |
    HER-2 negative
    |
    AiRuiKang (dalpiciclib) • famitinib (SHR 1020)
    A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. (NCT05670925)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    02/28/2023
    Initiation :
    03/01/2023
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    HER-2
    |
    HER-2 expression • PGR expression
    |
    AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)